VLST collaborate to create novel multi-antigen particular antibody therapeutics AnaptysBio.

AnaptysBio, VLST collaborate to create novel multi-antigen particular antibody therapeutics AnaptysBio, Inc eriacta.org http://eriacta.org ., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to create novel multi-antigen particular antibody therapeutics for the treating autoimmune and inflammatory disorders. This is actually the 4th collaboration announced by AnaptysBio during 2010. Antibodies produced by AnaptysBio will be developed and commercialized by VLST, a Seattle-based biotechnology organization focused on the development of therapeutics for autoimmune and inflammatory disorders. AnaptysBio offers received an upfront payment to initiate the collaboration and is certainly permitted receive milestone payments and royalties associated with the development and sale of any products produced from the collaboration.

Other Posts From Category "pharmacy news":

Related Posts